ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0799

Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study
Abstract Number: 0800

Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Abstract Number: 0801

Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
Abstract Number: 0802

Is There Any Relationship Between Helicobacter Pylori and Rheumatoid Arthritis?
Abstract Number: 0803

Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis
Abstract Number: 0804

Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Abstract Number: 0805

Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Abstract Number: 0806

Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
Abstract Number: 0807

High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
Abstract Number: 0808

Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Abstract Number: 0809

Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
Abstract Number: 0810

Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
Abstract Number: 0811

Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
Abstract Number: 0812

3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
Abstract Number: 0813

Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].